Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. (Q34328778)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23426043%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

0 references

Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23426043%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Matthieu Roustit

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23426043%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Jean-Luc Cracowski

6

object named as

Jean-Luc Cracowski

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23426043%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Sophie Blaise

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23426043%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Yannick Allanore

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23426043%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Patrick H Carpentier

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23426043%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Evren Caglayan

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23426043%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

0 references

publication date

20 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23426043%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23426043%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

72

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23426043%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23426043%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1696-1699

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23426043%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Clinical practice. Raynaud's Phenomenon

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202836

21 January 2018

Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202836

21 January 2018

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202836

21 January 2018

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202836

21 January 2018

Meta-analyses involving cross-over trials: methodological issues

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202836

21 January 2018

Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202836

21 January 2018

Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202836

21 January 2018

The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202836

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34328778&oldid=1626678267"